期刊文献+

HCV NS3丝氨酸蛋白酶及以其为靶位的抗感染研究进展

下载PDF
导出
摘要 丙型肝炎病毒感染最显著的特征是慢性化,已经成为严重的社会公共卫生问题。目前治疗方法仅限于干扰素-利巴韦林联合使用,持续疗效有限而且副作用大,因此迫切需要寻找特异有效的抗病毒药物。HCVNS3基因编码的NS3蛋白具有丝氨酸蛋白水解酶、解旋酶和磷酸核苷酶活性,在病毒RNA复制和多聚蛋白前体的加工成熟中有着重要作用。因此,NS3丝氨酸蛋白酶的抑制剂是抗病毒的理想药物。本文就HCVNS3丝氨酸蛋白酶及以其为靶位的抗感染研究综述如下。
出处 《国外医学(病毒学分册)》 2005年第4期97-100,共4页 Foreign Medical Sciences(Section of Virology)
  • 相关文献

参考文献27

  • 1Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. Journal of Hepatology, 1999, 31:25-30.
  • 2丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 3Seng-Lai Tan, et al,Strategies for hepatitis C therapeutic intervention: now and next, Current Opinion in Pharmacology, 2004, 4:465-470.
  • 4Mondelli MU, Silini E. Clinical significance of hepatitis C virus genotypes. Journal of Hepatology, 1999, 31:65-70.
  • 5World Health Organization. Hepatitis C - global prevalence (update). Weekly Epidemiological Record, 1999, 74:425-427.
  • 6Rosenberg, S. , Recent advances in the molecular biology of hepatitis C virus. J. Mol. Biol. 2001,313:451-/464.
  • 7Fried, M. W. , Advances in therapy for chronic hepatitis C. Clin.Liver Dis. 2001,5: 1009-/1023.
  • 8Zein, C. O.; Zein, N. N. Advances in therapy for hepatitis C infection. Microbes Infect. 2002, 4:1237 1246.
  • 9Rivas-Estilla, A. M.; Panduro, A. Molecular mechanisms of hepatitis C virus, potential therapeutic targets. Rev. Invest. Clin.2003, 55:51-64.
  • 10Hugle T, Cerny A: Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev Med Virol, 2003, 13:361-371.

二级参考文献15

  • 1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
  • 10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.

共引文献734

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部